Combining inhibition of mTORC1 or DNAPKC signaling with radio-chemotherapy has shown promising results in cancer therapy [17,18], suggesting that targeting L1CAM, which influences DNA repair and mTORC1 signaling, could be a valuable approach for further therapeutic exploration. This evidence concerns the gene PRKDC and cancer.